Okay. So no major dilution on company side should really be hitting, at all. That's good at least. I will definitely call him. I am more concerned with the progress and advancement of this project. Currently the only other proposals of tendon and other similar tissue repair involve some sort of stem cell therapy, and this alternative has extensive applications through a variety of fields, including a huge problem that has been hitting the news lately : care of our veterans. With the versatility of applications including treatment plans for diabetes and cardiac rehabilitation in terms of damaged tissue left from myocardial infarction (or valve damage in yours; I haven't forgotten), this could be one of the biggest treatment plans to hit medicine in a very long time. That could prove to grease a lot of wheels in movement and as far as presentation in funding. He needs to ensure his company is represented a bit better in standard, though, otherwise many are going to just assume that if he doesn't care about his own company, neither should they. This other project must be pretty damned amazing to distract him from the proliferation in value of TCEL so much.
I somewhat care about current PPS, but if this is the real deal, then to hell with it. I am just going to load up while it is down, and leave it in my pocket for the later date when the actuality of the value comes to the surface. I do like my quick gains, but this could be one of my very very very few long term holds.
News 
Market Data 
Discover 
AI
